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Abstract
Transplant recipients have elevated cancer risk, but it is unknown if cancer risk differs across race 
and ethnicity as in the general population. U.S. kidney recipients (N=87,895) in the Transplant 
Cancer Match Study between 1992 and 2008 were evaluated for racial/ethnic differences in risk 
for six common cancers after transplantation. Compared to white recipients, black recipients had 
lower incidence of non-Hodgkin lymphoma (NHL) (adjusted incidence rate ratio [aIRR] 0.60, 
p<0.001) and higher incidence of kidney (aIRR 2.09, p<0.001) and prostate cancer (aIRR 2.14, 
p<0.001); Hispanic recipients had lower incidence of NHL (aIRR 0.64, p=0.001), and lung (aIRR 
0.41, p<0.001), breast (aIRR 0.53, p=0.003) and prostate cancer (aIRR 0.72, p=0.05). Colorectal 
cancer incidence was similar across groups. Standardized incidence ratios (SIRs) measured the 
effect of transplantation on cancer risk and were similar for most cancers (p≥0.1). However, black 
and Hispanic recipients had larger increases in kidney cancer risk with transplantation (SIRs: 8.96 
in blacks, 5.95 in Hispanics vs. 4.44 in whites), and only blacks had elevated prostate cancer risk 
following transplantation (SIR: 1.21). Racial/ethnic differences in cancer risk after transplantation 
mirror general population patterns, except for kidney and prostate cancers where differences 
reflect the effects of end-stage renal disease or transplantation.
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Introduction
Kidney transplantation offers improved survival and quality of life compared to other 
treatments for end-stage renal disease (ESRD) [1]. These benefits are not without risk, 
however, including increased risk for cancer after transplantation [2-4]. The reasons for this 
increased risk are multifactorial and stem from a combination of decreased control of 
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oncogenic viruses due to the chronic immunosuppression necessary to prevent rejection, the 
high prevalence of certain chronic medical conditions associated with ESRD, and the 
intrinsic oncogenic properties of maintenance immunosuppression medications that may 
also contribute.
In the U.S. general population, cancer risk varies substantially across different races and in 
people of Hispanic ethnicity compared with non-Hispanics. Compared to whites, blacks 
have increased risk for cancers of the lung (among men), kidney, colorectum, prostate, 
pancreas, liver, and esophagus, as well as for multiple myeloma [5-10]. Blacks have 
decreased risk for non-Hodgkin lymphoma (NHL), breast cancer, and endometrial cancer 
compared to whites in the general population [5, 11-13]. Hispanics have increased risk for 
cancers of the cervix, liver, gall bladder, and stomach, and for acute lymphocytic leukemia, 
and decreased risk for cancers of the lung, colorectum, prostate, and breast compared to 
whites [14]. Many factors contribute to these differences, including differing environmental 
exposures, diets, occupations, health behaviors, genetics, socioeconomic status, access to 
health care, and cancer screening behaviors [15-22].
We are unaware of any previous research into racial/ethnic differences in cancer risk after 
transplantation. In the present study, we used several approaches to understand if different 
racial/ethnic groups face different risks for cancer after transplantation. First, we compared 
the incidence of common cancers among kidney recipients according to race/ethnicity. Since 
baseline (general population) cancer risks vary by race/ethnicity, we also explored whether 
the risk attributable to the transplant differed across groups. Finally, since risk of one of the 
cancers of interest (namely, kidney cancer) is elevated among people with ESRD [23, 24], 
and this increase could vary by race/ethnicity, we compared the risk of kidney cancer 
between kidney recipients and candidates on the transplant waitlist. We used data on more 
than 87,000 U.S. kidney recipients from the Transplant Cancer Match Study.
Methods
The Transplant Cancer Match Study links data from the Scientific Registry of Transplant 
Recipients (SRTR, 1987-2008) with 14 population-based U.S. cancer registries (http://
transplantmatch.cancer.gov/) [4]. The SRTR includes data on all solid organ transplants in 
the United States. Participating cancer registries, which together cover approximately 43% 
of the U.S. transplant population, ascertained the occurrence of malignancies (other than 
basal cell and squamous cell skin cancer) based on mandatory reporting from hospitals, 
medical providers, and pathology laboratories. Following linkage with the SRTR, 
investigators retain only anonymized data from the cancer registries. The study was 
approved by human subjects committees at the National Cancer Institute and, as required, at 
participating cancer registries.
In the present study, we included kidney-only recipients classified by the SRTR as white, 
black/African American, or Hispanic/Latino. The SRTR race/ethnicity variable is derived 
from kidney transplant candidate registry forms completed by transplant centers as required 
by participation in the U.S. transplant network. Multiple races/ethnicities may be marked for 
a given individual, although in practice more than 99% of candidates have a single race/
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ethnicity entered. In our analysis, any recipient with the category Hispanic/Latino indicated 
was included in our Hispanic category. This approach assumes that remaining recipients 
categorized as white are non-Hispanic whites, and those categorized as black are non-
Hispanic black, although it is likely that the white and black categories include some 
Hispanics.
For kidney recipients, follow-up started at transplantation and ended at death, graft failure, 
retransplantation, loss of follow-up by the transplant registry, or end of cancer registry 
coverage. Recipients were further restricted to those who received their transplant during 
years of cancer registry coverage between 1992 and 2008. We used the linked cancer 
registry data to identify incident cancers following transplantation. We focused on the six 
most common cancers after kidney transplantation: NHL, and cancers of the lung, kidney, 
colorectum, prostate, and breast. Breast cancer analyses were limited to female recipients; 
prostate cancer analyses were limited to male recipients.
Because kidney cancer incidence is markedly elevated in ESRD patients [23, 24], we 
assessed data for this cancer in candidates as well as recipients. We evaluated first-time 
candidates for kidney transplantation who were listed in the SRTR. Follow-up started on the 
date of first active waitlisting or January 1, 1992 (whichever was later) and continued until 
transplantation, death, or end of cancer registry coverage. We included 132,308 candidates 
residing in areas covered by participating cancer registries and followed during 1992-2008. 
As for recipients, kidney cancers were identified using linked cancer registry data.
Statistical analyses
For kidney recipients, we used Poisson regression to quantify racial/ethnic differences in 
cancer incidence (the number of cases observed per unit person-time at risk) after 
transplantation. Incidence rate ratios (IRRs) comparing recipients were adjusted for age at 
transplant (0-35, 36-50, 51-60, >60), gender, calendar year of transplant (1987-1996, 
1997-2003, 2004-2008), retransplantation (i.e., whether this was a first kidney vs. 
subsequent kidney transplant), and HLA mismatch (1-6 vs. 0).
As noted above, racial/ethnic differences in cancer incidence after transplantation could be 
caused by different baseline cancer incidence in the general population, different risks 
attributable to transplantation, or both. To test for differences in the effect of transplantation, 
we calculated the standardized incidence ratio (SIR) of each cancer of interest separately for 
each racial/ethnic group. The SIR compares cancer risk in kidney transplant recipients to 
people in the general population who are demographically similar, including in terms of 
race/ethnicity. The SIR is the observed count of cancers divided by the expected count, 
which is calculated by applying general population rates to person-time in the transplant 
cohort stratified by gender, age, race/ethnicity, and calendar year. For whites and blacks, the 
general population rates were derived from data from all participating cancer registries. For 
Hispanics, general population rates were from NCI's Surveillance, Epidemiology, and End 
Results program (SEER, www.seer.cancer.gov); because SEER data on Hispanics were first 
available in 1992, all kidney recipients transplanted in earlier years were excluded. We 
calculated 95% confidence intervals for the SIR using an exact method. We compared SIRs 
across racial/ethnic groups using Poisson regression. An elevated SIR (SIR>1) indicates an 
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increased risk for that cancer type after transplantation compared to the same racial/ethnic 
group in the general population, while a difference in SIRs between racial/ethnic groups 
implies that transplantation has a different effect on cancer risk across racial/ethnic groups.
Since kidney cancer is associated with ESRD, we did an additional set of analyses to clarify 
the relationship between race/ethnicity, ESRD, and kidney cancer risk. First, we calculated 
SIRs for kidney candidates vs. the general population, similar to the approach for recipients 
stratified by race/ethnicity. Second, we compared kidney cancer incidence in kidney 
recipients and candidates separately for each race/ethnic group, adjusting for attained age 
(0-14, 15-29, 30-44, 45-59, >59), gender, and attained calendar year (1992-1996, 
1997-2003, 2004-2008) using Poisson regression. We then assessed whether these IRRs 
differed across the race/ethnicity groups by testing for an interaction between candidate/
recipient status and race/ethnicity.
All p-values were two-sided and a p-value of 0.05 was considered significant. Analyses 
were performed using Stata 12.0/MP for Linux (StataCorp, www.stata.com, College Station, 
TX).
Results
There were 87,895 patients in the Transplant Cancer Match Study who underwent kidney 
transplantation between 1992 and 2008, of whom 56.7% were white, 23.5% black, and 
19.8% Hispanic. Demographic characteristics differed slightly among the racial/ethnic 
groups (Table 1). Black and Hispanic recipients were slightly younger (median age at 
transplant 45 years in blacks, 43 in Hispanics, vs. 47 in whites), less likely to have received 
a retransplantation, less likely to have zero HLA mismatches, and more likely to have 
undergone transplantation in the most recent calendar years.
As shown in Table 2, black kidney recipients had lower incidence of NHL (adjusted 
incidence rate ratio [aIRR] 0.60, 95% CI 0.46-0.77) and breast cancer (aIRR 0.62, 95% CI 
0.43-0.91), and higher incidence of kidney cancer (aIRR 2.09, 95% CI 1.68-2.60) and 
prostate cancer (aIRR 2.14, 95% CI 1.75-2.63) compared to white recipients. Hispanic 
recipients had lower incidence of NHL (aIRR 0.64, 95% CO 0.49-0.82), lung cancer (aIRR 
0.41, 95% CI 0.28-0.60), prostate cancer (aIRR 0.72, 95% CI 0.52-0.99) and breast cancer 
(aIRR 0.53, 95% CI 0.35-0.80) compared to white recipients.
Compared to the same racial/ethnic group in the general population, kidney recipients in all 
racial/ethnic groups had higher risk of NHL and kidney cancer (Table 3). SIRs for NHL 
were similar in the three racial/ethnic groups (ranging from 4.87 to 6.02), but the SIRs for 
kidney cancer in blacks and Hispanics were significantly higher than in whites (8.96 and 
5.95 vs. 4.44, Table 3). Lung cancer risk was approximately 30-40% higher than in the 
general population, with similar SIRs (1.33-1.39) in the three racial/ethnic groups. 
Colorectal cancer risk was similar to risk in the general population, and SIRs did not vary 
among the three groups. For breast cancer, female recipients in all groups had lower risk 
than the general population, although the deficit was most pronounced and statistically 
significant only for blacks (SIR 0.61, 95% CI 0.43-0.86). Among males, white and Hispanic 
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kidney recipients had lower risk of prostate cancer than the general population (SIRs 
0.70-0.75), but black recipients had a higher risk than the general population (SIR 1.21, 95% 
CI 1.03-1.42).
As shown in Table 4, kidney candidates in all racial/ethnic groups had increased risk of 
kidney cancer compared to the same racial/ethnic group in the general population. The SIR 
for kidney cancer in black candidates (14.20) was higher than in whites or Hispanics (5.87 
and 6.99, respectively; Table 4). Furthermore, kidney cancer risk was actually lower after 
transplant than in candidates of the same race/ethnicity. The degree of this reduction was 
similar across race/ethnicity (adjusted IRRs vs. candidates 0.68-0.86, p-values for 
interaction with race/ethnicity 0.28 for blacks and 0.61 for Hispanics).
Discussion
Among kidney recipients, risk for several common cancers differs by race/ethnicity. Black 
kidney recipients have a higher risk for kidney cancer and prostate cancer, and lower risk for 
NHL and breast cancer than white kidney recipients. Hispanic kidney recipients have a 
lower risk for NHL, lung cancer, prostate cancer, and breast cancer compared to white 
kidney recipients. We found that most of these racial/ethnic differences after transplantation 
were attributable to baseline differences in risks of cancer, since the cancer risk attributable 
to transplantation (as assessed by the SIR) was similar between races/ethnicities. We discuss 
below two exceptions to this pattern—kidney and prostate cancers—for which varying SIRs 
suggest different effects of transplantation and ESRD on risk across racial/ethnic groups.
First, though, we highlight that in the U.S. general population, racial/ethnic groups have 
different risks for each of the cancers that we studied. Compared to whites, blacks have 
increased risk for lung, kidney, colorectal, and prostate cancers while Hispanics have 
decreased risk for lung, kidney, and colorectal cancers [5, 14]. Causes for these racial/ethnic 
differences in baseline risk are varied and are posited to include differences in exposures, 
diet, health conditions, lifestyle, genetics, and screening rates [15-22]. In addition, cancer 
risk factors might have different effects across groups. For instance, there is evidence that 
blacks may have an increased susceptibility to cigarette smoke, while Hispanics may have 
decreased susceptibility [25, 26]. The incidence of NHL is lower for blacks than whites in 
the U.S. general population, although the explanation is unclear [27]. Differences in breast 
cancer risk may reflect differences in genetics or lifetime reproductive history, or perhaps 
variation in breast cancer screening related to healthcare access [19, 28-31].
Transplantation has a variable effect on risk for specific cancers [2-4]. A markedly elevated 
risk of NHL is largely due to the adverse effects of immunosuppression on control of 
Epstein-Barr virus infection [2-4]. An elevated risk for lung cancer with kidney 
transplantation has been demonstrated across studies and, among smokers, could be partly 
caused by chronic pulmonary inflammation or repeated lung infections [2-4, 32]. Among 
kidney recipients, risk for colorectal cancer is typically similar to the general population or 
slightly increased, while the risks of breast and prostate cancers are decreased [2, 3]. The 
reasons for the deficits in breast and prostate cancers are unclear, but one possibility is the 
effect of pre-transplant cancer screening. It is recommended that ESRD patients undergo 
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age-appropriate cancer screening before placement on the kidney waitlist [33]. If breast or 
prostate cancer were found, those patients would be ineligible for transplantation. Removal 
of such patients with cancer from the transplant population would lessen the incidence of 
these cancers among recipients after transplantation.
SIRs were similar across races/ethnicities with the exception of kidney cancer and prostate 
cancer. This finding suggests that for many cancer outcomes, the cancer risk attributable to 
transplantation is similar across racial/ethnic groups. That is, the biological effects of 
transplantation add to other risk factors to promote the development of cancer similarly 
across racial/ethnic groups, and transplantation preserves the relative ranking in cancer risk 
among groups. For example, in lung cancer, the prevalence of smoking or its effects may 
differ by race/ethnicity, but immunosuppression or other transplant-related factors amplify 
the risk associated with smoking with the same intensity across racial/ethnic categories. 
Among female recipients, the deficit of breast cancer appeared to be stronger in blacks than 
whites (Table 3), but the difference was of borderline significance (p=0.04).
In contrast, kidney cancer risk was elevated for all kidney recipients compared to the general 
population, but it increased more for black kidney recipients than for white or Hispanic 
recipients. However, when compared to kidney candidates, we observed that recipients 
actually had less risk. Thus, the increased risk for kidney cancer among black kidney 
recipients does not appear to be attributable to transplantation: instead there are strong 
racial/ethnic differences in risk among kidney candidates. Given the association of kidney 
cancer with acquired polycystic kidney disease (APKD) and the increased prevalence of 
APKD with time on dialysis [34, 35] the difference among black candidates may partly 
result from longer waitlist time and time on dialysis for blacks compared to whites [36, 37]. 
The amplification of kidney cancer risk associated with ESRD in blacks could also be a 
result of racial differences in the primary cause of ESRD or the prevalence of obesity or 
uncontrolled hypertension [38]. The effect of hypertension on development of kidney cancer 
may be stronger in blacks than whites and could explain our findings [39].
For prostate cancer, the risk was lower in white and Hispanic kidney recipients than in the 
general population, while for black men the risk was actually increased after transplantation. 
Because a large fraction of prostate cancers are detected in asymptomatic men due to 
screening [40], one possibility is that black kidney recipients received more prostate cancer 
screening than whites and Hispanics. In turn, higher rates of screening in black kidney 
recipients could have been driven by clinicians’ recognition of a higher risk of prostate 
cancer among black men in the general population.
Strengths of our study include use of a large, nationally representative cohort of ethnically 
diverse kidney recipients. Cancer ascertainment was based on cancer registry data with 
mandatory reporting, and was reliable and uniform across racial/ethnic groups. Nonetheless, 
any study that examines differences in racial/ethnic groups must acknowledge the imperfect 
nature of these classifications. We relied on transplant centers’ classification of recipients at 
the time of initial evaluation for transplantation, and the white and black categories likely 
included an unknown proportion of Hispanics. Furthermore, our Hispanic category 
represents a heterogeneous population in terms of genetic background, culture, and duration 
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of U.S. residence. In general, race/ethnicity serves as a marker for other genetic, exposure, 
and lifestyle factors [41]. Although we conjectured that racial/ethnic differences in screening 
rates for cancers before and after transplantation could have contributed to variation in 
cancer risk, we do not have data on cancer screening practices among transplant candidates 
or recipients. In addition, we lacked data on other health behaviors and exposures that could 
have impacted cancer risk.
To conclude, we found that cancer risk varies by race/ethnicity in kidney recipients. For the 
most part, these differences parallel the patterns seen in the general population, suggesting 
that transplantation has a consistent effect across groups on underlying biological processes 
and preserves the underlying racial/ethnic differences in cancer risk. Nonetheless, the risk 
attributable to transplantation or ESRD for kidney and prostate cancer was increased in 
blacks compared to whites or Hispanics. Further research should aim to elucidate the 
mechanisms that underlie racial/ethnic differences in cancer risk among transplant recipients 
and candidates and to determine optimal cancer screening and prevention measures.
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Table 1
Demographic characteristics of U.S. kidney recipients in the Transplant Cancer Match Study by race/ethnicity
White N (%) 49,827 (100) Black N (%) 20,678 (100) Hispanic N (%) 17,390 (100)
Age at transplant, years
    0-35 12,709 (25.5) 5,635 (27.3) 6,176 (35.5)
    36-50 16,415 (32.9) 7,420 (35.9) 5,428 (31.2)
    51-60 11,863 (23.8) 4,951 (23.9) 3,543 (20.4)
    >60 8,840 (17.7) 2,672 (12.9) 2,243 (12.9)
Gender
    Male 30,139 (60.5) 12,094 (58.5) 10,363 (59.6)
    Female 19,688 (39.5) 8,584 (41.5) 7,027 (40.4)
Calendar year of transplant
    1992-1996 12,176 (24.4) 4,190 (20.3) 3,215 (18.5)
    1997-2003 23,056 (46.3) 9,545 (46.1) 7,772 (44.7)
    2004-2008 14,595 (29.3) 6,943 (33.6) 6,403 (36.8)
Retransplantation
    No 44,052 (88.4) 19,051 (92.1) 15,992 (92.0)
    Yes 5,775 (11.6) 1,627 (7.9) 1,398 (8.0)
HLA mismatches
    0 8,406 (16.9) 1,409 (6.8) 2,539 (14.6)
    1-6 40,935 (82.2) 19,129 (92.5) 14,670 (84.4)
    Missing 486 (1.0) 140 (0.7) 181 (1.0)
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Table 3
Comparison of cancer risk in kidney recipients with risk in the general population, according to race/ethnicity
Cancer Outcome Standardized incidence ratio (95% CI) P-value for difference in SIRs
White Black Hispanic Black vs. white Hispanic vs. white
NHL 6.02 (5.43-6.68) 4.87 (3.80-6.14) 5.57 (4.37-6.99) 0.1 0.5
Lung cancer 1.39 (1.23-1.57) 1.34 (1.08-1.63) 1.33 (0.89-1.91) 0.7 0.8
Kidney cancer 4.44 (3.84-5.09) 8.96 (7.54-10.57) 5.95 (4.63-7.53) <0.001 0.02
Colorectal cancer 0.94 (0.78-1.12) 0.93 (0.68-1.23) 0.75 (0.47-1.13) 0.9 0.3
Prostate cancer 0.75 (0.65-0.85) 1.21 (1.03-1.42) 0.70 (0.51-0.94) <0.001 0.7
Breast cancer 0.91 (0.77-1.06) 0.61 (0.43-0.86) 0.77 (0.50-1.12) 0.04 0.4
Standardized incidence ratios (SIR) are the observed count of each cancer divided by the expected count calculated by applying general population 
rates to person-time in the transplant cohort stratified by gender, age at transplant, race/ethnicity, and calendar year of transplant. General 
population rates were derived from all participating cancer registries (whites and blacks) and SEER registries (Hispanics). Poisson regression was 
used to compare SIRs between racial/ethnic groups.
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Table 4
Comparison of kidney cancer risk in candidates for kidney transplantation, kidney recipients, and the general 
population, according to race/ethnicity.
White Black Hispanic
SIR in candidates (95% CI) 5.87 (5.15-6.65) 14.20 (12.85-15.64) 6.99 (5.77-8.40)
SIR in recipients (95% CI) 4.44 (3.84-5.09) 8.96 (7.54-10.57) 5.95 (4.63-7.53)
aIRR for recipients vs. candidates (95% CI) 0.80 (0.65-0.97) 0.68 (0.57-0.81) 0.86 (0.66-1.13)
Standardized incidence ratios (SIR) are the observed count of each cancer divided by the expected count calculated by applying general population 
rates to person-time in the cohort stratified by those variables available for both recipients and candidates, namely: gender, attained age, race/
ethnicity, and attained year. General population rates were derived from all participating cancer registries (whites and blacks) and SEER registries 
(Hispanics). Poisson regression was used to compare adjusted incidence rates (aIRR) between recipients and candidates and to test for interaction 
by racial/ethnic group.
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